Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Fused or hybrid cell – per se
Reexamination Certificate
2005-02-01
2005-02-01
Li, Q. Janice (Department: 1632)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Fused or hybrid cell, per se
C435S325000, C435S347000, C435S440000, C435S449000, C424S093100, C436S063000, C436S164000, C436S172000
Reexamination Certificate
active
06849451
ABSTRACT:
A rapid, simple-to-use method for preparing hybrid cells, applicable to fully differentiate, non-dividing cells, entails bringing at least two different cells into contact under conditions that promote cell fusion and then purifying the resultant hybrid without antibiotic or metabolic selection. This approach yields hybrid cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.
REFERENCES:
patent: 4762701 (1988-08-01), Horan et al.
patent: 4783401 (1988-11-01), Horan et al.
patent: 4859584 (1989-08-01), Horan et al.
patent: 6197593 (2001-03-01), Deka et al.
patent: 6652848 (2003-11-01), Gong et al.
patent: WO 9003576 (1990-04-01), None
patent: WO 9630030 (1996-10-01), None
patent: WO 9846785 (1998-10-01), None
Koolwijk et al. enrichment and selection of hybrid hybridomas by percoll density gradient centrifugation and foluroescent-activated cell sorting pp. 217-225 No. 2 1988.*
Ohkohchi et al. New technique for producing hybridoma by using laser radiation Apr. 18. 2002.*
Wagner et al. A somatic cell hybrid panel for distal 17q: GDIA1 maps to 17q25.3 pp. 172-175 1997.*
Abbas et al, Cellular and Molecular Immunology, 1999.*
Schaap, G. H. t al.,Differentiation,“Gene Expression in Flow Sorted Mouse Terato Carcinoma X Human Fibroblast Heterokaryons” 1984, vol. 26, No. 2, pp. 127-133.
Holmes L. M. et al.,Journal of Immunotherapy,“A rapid, Novel Strategy to Induce Tumor Cell-Specific Cytotoxic T Lymphocyte Responses Using Instant Dendritomas.” Mar.-Apr. 2001) vol. 24, No. 2, pp 122-129.
Stryer,Biochemie,Spektrum der Wissenschaften GmbH, 1990, pp. 931-933.
Parkinson et al., “Cytokines: Biology And Applications in Cancer Medicine”, in Cancer Medicine, 4thed., pp. 1213-1226.
Philip et al., “Treatment Of Malignant Melanoma With Interleukin-2,”Seminars in Oncology,vol. 24(1):S4-32-Sr-38, (1997.
Smith et al., “Immune And Gene Therapy For Melanoma, And The Immunobiology Of Melanoma”,Internaitonal Journal Of Dermatology,Blackwell Science Ltd., vol. 38:490-508, (1999).
Boon et al., “Tumor Antigens Recognized By T Cells”, Elsevier Science Ltd., vol. 18:267-268, (1997).
Stockert et al., “A Survey Of The Humoral Immune Response Of Cancer Patients To A Panel Of Human Tumor Antigens”,J. Exp. Med.,The Rockefeller University Press, vol. 187(8):1349-1354, (1998).
Sahin et al., “Human Neoplasms Elicit Multiple Specific Immune Responses In The Autologous Host”,Proc. Natl. Acad. Sci. USA,Immunology, vol. 92:11810-11813, (1995).
Gabrilovich et al., “Production of Vascular Endothelial Growth Factor By Human Tumors Inhibits the Functional Maturation Of Dendritic Cells”,Nature Medicine,vol. 2(10):1096-1103, (1996).
Ishida et al., “Defective Function Of Langerhans Cells in Tumor-Bearing animals Is The Result of Defective Maturation From Hemopoietic Progenitors”,The Journal of Immunology,The American Association of Immunologists, pp. 4842-4851, (1998).
Steinman, “The Dendritic Cell System And Its role In Immunogenicity”,Annu. Rev. Immunol.,Annual Reviews Inc., vol. 9:271-296, (1991).
Macatonia et al., “Primary Stimulation By Dendritic Cells Induces Antiviral proliferative And Cytotoxic T Cell Responses in Vitro”,J. Exp. Med.,The Rockefeller University Press, vol. 169:1255-1264, (1989).
Mehta-Damani et al., “Generation Of Antigen-Specific CD8+ CTLs From Naïve Precursors”,The Journal of Immunology,The American Association Of Immunologists, vol. 153:996-1004, (1994).
Porgador et al., “Bone Marrow-Generated Dendritic Cells Pulsed With A Class I-Restricted peptide Are Potent Inducers Of Cytotoxic T Lymphocytes”,J. Exp. Med.,The Rockefeller University Press, vol. 182:255-260, (1995).
Young et al., “Dendritic Cells As Adjuvants For Class I Major Histocompatibility Complex-Restricted Antitumor Immunity”,J. Exp. Med.,The Rockefeller University Press, vol. 183:7-12, (1996).
Mayordomo et al., “Bone-Marrow-Derived Dendritic Cells Pulsed With Synthetic Tumour Peptides Elicit Protective And Therapeutic Antitumour Immunity”,Nature Medicine,vol. 1(23):1297-1303, (1995).
Bakker et al., “Generation Of Antimelanoma Cytotoxic T Lymphocytes From health Donors After Presentation of melanoma-Associated Antigen-Derived Epitopes by Dendritic Cells in Vitro”,Cancer Research,vol. 55:5330-5334, (1995).
Flamand et al., “Murine Dendritic Cells pulsed In Vitro With Tumor Antigen Induce Tumor Resistance in Vitro”,Eur. J. Immunol.,VCH Veerlagsgeselischaft mbH, vol. 24:605-610, (1994).
Gong et al., “Induction Of Antigen-Specific Antitumor Immunity With Adenovirus-Transduced Dendritic Cells”,Gene Therapy,Stockton Press, vol. 4:1023-1028, (1997).
Song et al., “Dendritic Cells Genetically Modified With An Adenovirus Vector Encoding The cDNA For A Model Antigen Induce Protective And Therapeutic Antitumor Immunity”,J. Exp. Med.,The Rockefeller University Press, vol. 186(8):1247-1256, (1997).
Specht et al., “Dendritic Cells Retrovirally Transduced With A Model Antigen Gene Are Therapeutically Effective Against Established Pulmonary Metastases”,The Journal Of Experimental Medicine,vol. 186(8):1213-1221, (1997).
Rosenberg et al., “Immunologic And Therapeutic Evaluation Of A Synthetic Peptide Vaccine For The Treatment of Patients With Metastatic Melanoma”,Nature Medicine,vol. 4(3):321-327, (1998).
Wallack et al., “A Phase III Randomized, Double-Blind, Multiinstitutional Trial Of Vaccinia Melanoma Oncolysate-Active Specific Immunotherapy For Patients With Stage II Melanoma”,Cancer,vol. 74(1):34-42, (1995).
Bystryn, “Clinical Activity of A Polyvalent Melanoma Antigen Vaccine”, Springer-Verlag Berlin, vol. 139:337-348, (1995).
Mitchell, “Perspective On Allogeneic Melanoma Lysates in Active Specific Immunotherapy”,Seminars In Oncology,vol. 25(6):623-635, (1998).
Morton et al., “Polyvalent Melanoma Vaccine Improves Survival Of Patients With Metastatic Melanoma”,Ann. N.Y. Acad. Sci.,vol. 690:120-134 (1993).
Berd et al., “Autologous, Hapten-Modified Vaccine As A Treatment For Human Cancers”,Seminars in Oncology,vol. 25(6):646-653, (1998).
Berd et al., “Autologous Hapten-Modified Melanoma Vaccine As Postsurgical Adjuvant Treatment After Resection Of Nodal Metastases”,Journal Of Clinical Oncology,vol. 15(6):2359-2370, (1997).
Shurin, “Dendritic Cells Presenting Tumor Antigen”,Cancer Immunol. Immunother,vol. 43:158-164, (1996).
Haigh et al., “Vaccine Therapy For patients With Melanoma”,Oncology,vol. 13(11):1561-1574, (1999).
Gong et al., “Induction Of Antitumor Activity By Immunization With Fusions Of Dendritic And Carcinoma Cells”,Nature Medicine,vol. 3(5):558-561, (1997).
Wang et al., “Eliciting T Cell Immunity Against Poorly Immunogenic Tumors By Immunization With Dendritic Cell-Tumor Fusion Vaccines”,The Journal Of Immunology,The American Association of Immunologists, vol. 161:5516-5524, (1998).
Lespagnard et al., “Dendritic Cells Fused With Mastocytoma Cells Elicit Therapeutic Antitumor Immunity”,Int. J. Cancer,vol. 76:250-258, (1998).
Rowse et al., “Tolerance And Immunity To MUC1 In A Human MUC1 Trangenic Murine Model”,Cancer Research,vol. 53:315-321, (1998).
Abbas et al., “Cellular and Molecular Immunology”, Saunders Text and Review Series, pp. 347-350.
Wei et al., “Long-Term Expression Of Human Growth Hormone (hGH) In Mice Containing Allogeneic Yolk Sac Cell Derived Neovascular Implants Expressing hGH”,Stem Cells,vol. 14:2320238, (1996).
Horan et al., “Stable Cell Membrane Labelling”,Nature,vol. 340:167-168, (1989).
Horan et al., “Fluorescent Cell Labelling For In Vivo And In Vitro Cell Tracking”,Methods In Cell Biology,Academic Press, Inc., vol. 33:469-491
Wagner Thomas E.
Wei Yanzhang
Foley & Lardner LLP
Greenville Hospital System
Li Q. Janice
LandOfFree
Hybrid cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3466623